Physician organizations have an ethical obligation to advocate for general improvement of public health, even if it is sometimes at the expense of interests of medical professionals.
Mark McClellan, Commissioner of Food and Drugs, discusses pharmaceutical company research and the problems faced by funding for public health programs.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
While there are benefits to genetic screening during pregnancy, parents must not let their desire for a genetically perfect child allow them to terminate a pregnancy because of non-medical factors.